KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.

Ann Oncol · 2025-Nov · PMID 40680993

Panel KM_panel提取完成待 EXE 对齐验证

overall survival

Figure 1.. Intention-to-treat analysis of overall survival (key secondary efficacy endpoint). ARPI, androgen receptor pathway inhibitor; CI, confidence interval; no., number; PSMA, prostate-specific membrane antigen.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.87
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:49:49+00:00